These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 30070630)

  • 41. Role of biochemical markers in the management of osteoporosis.
    Henriksen K; Christiansen C; Karsdal MA
    Climacteric; 2015; 18 Suppl 2():10-8. PubMed ID: 26507704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Utility of Biomarkers in Osteoporosis Management.
    Garnero P
    Mol Diagn Ther; 2017 Aug; 21(4):401-418. PubMed ID: 28271451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Significance of Bone Turnover Marker Measurement in the Treatment of Osteoporosis].
    Miura M; Satoh Y
    Yakugaku Zasshi; 2019; 139(1):27-33. PubMed ID: 30606924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.
    Diez-Perez A; Naylor KE; Abrahamsen B; Agnusdei D; Brandi ML; Cooper C; Dennison E; Eriksen EF; Gold DT; Guañabens N; Hadji P; Hiligsmann M; Horne R; Josse R; Kanis JA; Obermayer-Pietsch B; Prieto-Alhambra D; Reginster JY; Rizzoli R; Silverman S; Zillikens MC; Eastell R;
    Osteoporos Int; 2017 Mar; 28(3):767-774. PubMed ID: 28093634
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature.
    Deas CM; Murphy P; Iranikhah M; Freeman MK
    Consult Pharm; 2017 Mar; 32(3):144-155. PubMed ID: 28270269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prediction by early change of bone metabolic markers of the efficacy of anti-osteoporotic drugs on bone mass in osteoporotic patients].
    Inaba M
    Clin Calcium; 2014 Mar; 24(3):379-84. PubMed ID: 24576934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monitoring pharmacological therapy for osteoporosis.
    Lewiecki EM
    Rev Endocr Metab Disord; 2010 Dec; 11(4):261-73. PubMed ID: 20143165
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical usefulness of bone turnover markers with the treatment of osteoporosis].
    Miura M
    Clin Calcium; 2014 Mar; 24(3):367-76. PubMed ID: 24576933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of statins for osteoporosis: a systematic review and meta-analysis.
    An T; Hao J; Sun S; Li R; Yang M; Cheng G; Zou M
    Osteoporos Int; 2017 Jan; 28(1):47-57. PubMed ID: 27888285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is there a place for bone turnover markers in the assessment of osteoporosis and its treatment?
    Devogelaer JP; Boutsen Y; Gruson D; Manicourt D
    Rheum Dis Clin North Am; 2011 Aug; 37(3):365-86, v-vi. PubMed ID: 22023897
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone turnover: Biology and assessment tools.
    Szulc P
    Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.
    Lee J; Vasikaran S
    Ann Lab Med; 2012 Mar; 32(2):105-12. PubMed ID: 22389876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Denosumab After Treatment Discontinuation : A Review of the Literature.
    Iranikhah M; Deas C; Murphy P; Freeman MK
    Consult Pharm; 2018 Mar; 33(3):142-151. PubMed ID: 29720299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone turnover marker monitoring in osteoporosis treatment response.
    Tan RZ; Loh TP; Vasikaran S
    Eur J Endocrinol; 2020 Jun; 183(1):C5-C7. PubMed ID: 32504486
    [No Abstract]   [Full Text] [Related]  

  • 55. Goal-directed treatment of osteoporosis in Europe.
    Kanis JA; McCloskey E; Branco J; Brandi ML; Dennison E; Devogelaer JP; Ferrari S; Kaufman JM; Papapoulos S; Reginster JY; Rizzoli R
    Osteoporos Int; 2014 Nov; 25(11):2533-43. PubMed ID: 25199574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring osteoporosis treatment.
    Compston J
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):781-8. PubMed ID: 19945689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of bisphosphonates on osteoporosis: Focus on zoledronate.
    Oryan A; Sahvieh S
    Life Sci; 2021 Jan; 264():118681. PubMed ID: 33129881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone turnover markers: understanding their value in clinical trials and clinical practice.
    Civitelli R; Armamento-Villareal R; Napoli N
    Osteoporos Int; 2009 Jun; 20(6):843-51. PubMed ID: 19190842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone turnover markers to monitor oral bisphosphonate therapy.
    Ashcherkin N; Patel AA; Algeciras-Schimnich A; Doshi KB
    Cleve Clin J Med; 2023 Jan; 90(1):26-31. PubMed ID: 36596600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density.
    van der Burgh AC; de Keyser CE; Zillikens MC; Stricker BH
    Drugs; 2021 Nov; 81(16):1831-1858. PubMed ID: 34724173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.